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It has been found that honey ameliorates cardiovascular risk factors in healthy 
individuals and in patients with elevated risk factors. The present study investigated the 
effect of natural honey on total cholesterol, low-density lipoprotein cholesterol (LDL-C), 
high-density lipoprotein cholesterol (HDL-C), triacylglycerole, C-reactive protein (CRP), 
fasting blood glucose (FBG), and body weight in overweight individuals. There were 55 
patients, overweight or obese, who were randomly recruited into the study and assigned 
into two groups: control group (17 subjects) and experimental group (38 subjects). 
Patients in the control group received 70 g of sucrose daily for a maximum of 30 days 
and patients in the experimental group received 70 g of natural honey for the same 
period. In the control and experimental groups, body weight, body mass index, body fat 
weight, total cholesterol, LDL-C, HDL-C, triacylglycerole, FBG, and CRP were measured 
before treatment and at day 31 after the commencement of treatment. Results showed 
that honey caused a mild reduction in body weight (1.3%) and body fat (1.1%). Honey 
reduced total cholesterol (3%), LDL-C (5.8), triacylglycerole (11%), FBG (4.2%), and CRP 
(3.2%), and increased HDL-C (3.3%) in subjects with normal values, while in patients with 
elevated variables, honey caused reduction in total cholesterol by 3.3%, LDL-C by 4.3%, 
triacylglycerole by 19%, and CRP by 3.3% (p < 0.05). It is our conclusion that 
consumption of natural honey reduces cardiovascular risk factors, particularly in 
subjects with elevated risk factors, and it does not increase body weight in overweight or 
obese subjects. 
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INTRODUCTION 
Honey has been used for as long as there has been medicine. The ancient Sumerians, Babylonians, and 
Egyptians all recorded its use, e.g., in Sumerian clay tablets estimated to be 4,000 years old and in 
Egyptian papyri dated from 1900–1250 B.C. The ancient Egyptians used honey in embalming and made 
salves with it for treating diseases of the eye and skin.; honey was used as a drug more than a nutrient. 
Honey was valued highly in the Middle East and was mentioned in the Holy Quran 1,400 years ago. 
(“And the LORD taught the bee to build its cells in hills, on tree and in men’s habitations, then to eat of 
all the produce of the earth and find with skill the spacious paths of its LORD, there issues from within 
their bodies a drink of varying colors, wherein is healing for men, verily in this is a sign for those who 
give thought.”) It was also mentioned in the Holy Talmud and Holy Bible. Avicenna (Ebne Sina), the 
famous Persian philosopher and physician about 1,000 years ago, mentioned the therapeutic effect of 
honey in Ghanoon, his published book[1]. 
There are over 300 types of floral honey available in the marketplaces of the world. The color, flavor, 
and mineral and vitamin content of honey depend on the flower from which bees gather the nectar. In 
modern medicine, honey has been used for the treatment of respiratory disease, urinary disease, 
gastrointestinal disease, skin ulcers, wounds, eczema, psoriasis, dandruff, diaper dermatitis, and radiation 
mucositis[2,3,4,5,6,7,8]. Laboratory studies and clinical trials have shown that honey shows a broad-
spectrum antimicrobial activity[9,10,11,12,13], and increases antibody production against thymus-
dependent and thymus-independent antigens[14]. Consumption of honey decreases the concentrations of 
prostaglandins in the plasma of normal individuals[15], and increases antioxidant agents, serum iron, and 
blood indices[16]. Honey increases insulin secretion and decreases blood glucose levels[17,18,19]. Al-
Waili found that natural honey also improves lipid profile, lowers normal and elevated C-reactive protein 
(CRP), lowers homocysteine, and decreases triacylglycerole in patients with hypertriglyceridemia[19]. 
The ability of honey to modulate total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-
density lipoprotein cholesterol (HDL-C), triacylglycerole, homocysteine, and CRP carries a potential role 
of using honey to reduce cardiovascular risk factors. Honey contains glucose and fructose. Fructose or 
glucose affects total cholesterol, triacylglycerole, and other risk factors. The purpose of this study is to 
investigate the effect of natural honey collected from Iran on cardiovascular risk factors, such as total 
cholesterol, LDL-C, HDL-C, triacylglycerole, CRP, and body weight, in overweight or obese subjects 
with normal or elevated cardiovascular risk factors; sucrose was used as control because it is commonly 
used as a sweetener and it contains glucose and fructose. 
MATERIALS AND METHODS 
Subjects 
There were 60 overweight or obese subjects (body mass index [BMI] >25 kg/m
2), aged between 20 and 
60 years, who were randomly recruited from the educational department of Mashhad University of 
Medical Science. Subjects were randomly allocated to either the experimental group (n = 40) or a control 
group (n = 20). Subjects who were <20 or >60 years old were excluded from the study, as were subjects 
who used any medications. Among them, 55 subjects remained in either the experimental group (n = 38, 
age 42.6 ± 8.6 years) or the control group (n = 17, age 39.6 ± 10.6 years). There were 24 males and 31 
females, and the mean age of subjects was 41.2 ± 9.2 years.  
Subjects in the control group received 70 g of sucrose dissolved in 250 ml tap water daily, while 
subjects in the experimental group received 70 g of honey dissolved in 250 ml tap water each day for a 
maximum of 30 days. Subjects in both groups did not undergo a special diet regimen, drug therapy, or 
change in their lifestyle, such as physical exercise, during the period of study. Natural unprocessed honey 
was used for experimentation.  Yaghoobi et al.: Honey and Cardiovascular Risk Factors  TheScientificWorldJOURNAL (2008) 8, 463–469 
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The subjects were followed and any side effects on using the interventions were recorded. Any new 
symptom that appeared after commencement of intervention intake was considered a side effect and 
recorded. 
Each subject gave informed written consent to participate in the study, which was approved by the 
Mashhad University of Medical Science Ethics Committee. 
Anthropometric Measurements 
Anthropometric parameters, including weight, height, and waist circumference, were determined before 
and after intervention using a standard protocol. Subjects were asked to breathe normally and to breathe 
out gently at the time of the measurement. Height and body weight were measured with the subjects 
dressed in light clothing after an overnight fast. The body weight of each subject was measured with a 
standard scale to an accuracy of ±0.1 kg and height was measured to an accuracy of ±0.1 cm. The BMI 
was calculated as weight (kg) divided by height squared (m
2).  
Body fat percentage (BF%) and body fat weight (BFW) were measured before interventions and 
repeated after 30 days. BF% and BFW were measured by a hand-held Bio impedance analyzer with the 
CV of less than 1%. 
Routine Biochemical Analysis 
Blood samples were collected in the morning after an overnight fast from each subject. Laboratory data, 
including full fasting lipid profile comprising total cholesterol and HDL-C, LDL-C, triacylglycerole, and 
fasting blood glucose (FBG), were determined for each patient. All of the above were measured by 
routine methods. Hs-CRP was measured by a high-sensitivity PEG-enhanced immunoturbidimetry 
method with an Alycon analyzer (ABBOTT, Chicago, IL). The within assay and between assay precision 
was less than 1% for all biochemical assays. These variables were repeated 30 days after commencement 
of intervention intake.  
Statistical Analysis 
Statistical analysis was undertaken with the use of MINITAB
 software (release 13; Minitab Inc., State 
College, PA). Paired t-test to compare between means before and after intervention in the same group and 
unpaired t-test to compare between control and honey group were used for statistical analysis; p < 0.05 
was considered as statistically significant. Categorical data were compared by using
 Fisher’s exact test or 
chi-square test. Analysis of covariance was used
  to assess differences after adjustment for important 
confounding
 factors, such as age and physical activity. 
RESULTS 
There were no statistically significant differences in the mean values of age, BMI, BF%, lipid profiles, 
and fasting blood glucose (FBG) between the control and experimental groups (p > 0.05, Tables 1 and 2). 
However, the sucrose group was significantly heavier than the honey group; they were approximately 10 
kg heavier than the experimental group (p < 0.05, Table 1). Tables 1 and 2 demonstrate the effects of 
sucrose or honey intake on body weight, body fat, lipid profile, FBG, and CRP. The results showed that 
honey caused significant reduction of BMI (1.14%, p = 0.02) and FBG (4.2%, p = 0.04) in subjects with 
normal values (Tables 1 and 2). Also, honey significantly reduced serum triacylglycerole (19%,   
p = 0.006) and hs-CRP (3.3%, p = 0.008) in subjects with elevated variables (Tables 1 and 2). However,  Yaghoobi et al.: Honey and Cardiovascular Risk Factors  TheScientificWorldJOURNAL (2008) 8, 463–469 
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TABLE 1 
Effects of Sucrose and Honey on Anthropometric Measurements and Serum Triacylglycerole 
  Age (Years)  Weight (kg)  BF%  Weight Fat (kg) 
Type of 
treatment 
S  H S H  S  H S H 
Number 17  38 17 38  17  38 17 38 
Before 42.4 ± 8.7 39.6 ± 10.6 87.6 ± 11.3 77.4 ± 9.4 32.4 ± 9.9 34.0 ± 6.8 28.5 ± 10.9 26.3 ± 5.9 
After —  —  88.1 ± 11.7 76.4 ± 9.2 32.7 ± 9.4 33.4 ± 7.5 29.3 ± 10.7 26.0 ± 7.5 
p Value  —  —  0.07  0.09 0.511  0.279 0.175  0.682 
Changes (%)  —  —  ↑ 0.6  ↓1.3  ↑0.9  ↓1.8  ↑2.8  ↓1.1 
  BMI (kg/m
2) Triacylglycerole 
(mg/dl) 
Triacylglycerole  
>150 mg/dl 
  
Type of 
treatment 
S H  S  H S H     
Number 17  38 17 38  10  15     
Before 32.6 ± 6.6 30.1 ± 3.1 183 ± 108 156 ± 80 250 ± 110 237 ± 56    
After 32.8 ± 5.0 29.8 ± 3.2 182 ± 132 139 ± 67 240 ± 162 192 ± 59    
p Value  0.199  0.02  0.988 0.171  0.801  0.006     
Changes (%)  ↑0.4  ↓1.2  ↓0.6  ↓11  ↑↓4  ↓19    
Note:  Values are expressed as Mean ± SD, or percentages. Comparison between pre- and post-treatment were 
assessed by paired t-test. T-test was used for comparison between pretreatment honey and sucrose subjects, and 
only sucrose group was significantly heavier than honey group (p < 0.05). S = sucrose; H = honey. 
TABLE 2 
Effects of Sucrose and Honey on Biochemical Markers  
  Hs-CRP (mg/dl)  Hs-CRP >5 mg/dl  LDL-C (mg/dl)  LDL-C >130 (mg/dl) 
Type  of  treatment  S H S H S H  S  H 
Number  17  38 3 17  17  38  6  21 
Before  4.8 ± 3.2  6.3 ± 4.2  9.9 ± 3.6  9.8 ± 2.8  127 ± 40  137 ± 46  165 ± 11.8  164 ± 28 
After  4.7 ± 3.1  6.1 ± 4.1  9.8 ± 3.1  9.5 ± 2.8  130 ± 49  129 ± 53  180 ± 30  157 ± 37 
p Value  0.421  0.28  0.89  0.008 0.671 0.062  0.216  0.204 
Changes (%)  ↓ 2  ↓ 3.2  ↓ 1  ↓ 3.3  ↑ 2.4  ↓ 5.8  ↑ 9  ↓ 4.3 
  TC (mg/dl)  TC >200 (mg/dl)  HDL-C (mg/dl)  FBG (mg/dl) 
Type  of  treatment  S H S H S H  S  H 
Number  17 38 13 30 17 38  17  38 
Before  220 ± 39  226 ± 50  237 ± 25  242 ± 39  56 ± 13  60 ± 14.1  93.2 ± 14.7  96.2 ± 44.2 
After  223 ± 46  219 ± 57  239 ± 42  234 ± 52  58 ± 15  62 ± 14.8  95.3 ± 18.4  92.2 ± 39.2 
p Value  0.368  0.165  0.844  0.137 0.308  0.40  0.341  0.042 
Changes (%)  ↑ 1.4  ↓ 3  ↑ 0.8  ↓ 3.3  ↑ 3.6  ↑ 3.3  ↑ 2.2  ↓ 4.2 
Note:  Values are expressed as Mean ± SD, or percentages. Comparison between pre- and post-treatment were assessed by 
paired t-test. T-test was used for comparison between pretreatment honey and sucrose subjects and no significant 
differences were observed (p > 0.05). S = sucrose; H = honey; Hs-CRP = high-sensitivity C-reactive protein; LDL-C = 
low-density lipoprotein cholesterol; TC = total cholesterol; HDL-C = high-density lipoprotein cholesterol; FBG = fasting 
blood glucose.  
honey consumption had a nonsignificant mild reduction in body weight (1.3%), BF% (1.8%), and BFW 
(1.1%) (p > 0.05, Table 1). Honey nonsignificantly reduced total cholesterol (3%), LDL-C (5.8%), 
triacylglycerole (11%), and CRP (3.2%), and increased HDL-C (3.3%) in subjects with normal values (p Yaghoobi et al.: Honey and Cardiovascular Risk Factors  TheScientificWorldJOURNAL (2008) 8, 463–469 
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> 0.05), while in subjects with elevated variables, honey caused a reduction in total cholesterol by 3.3% 
and LDL-C by 4.3% (p > 0.05, Tables 1 and 2).  
No significant changes were found in anthropometric measurement and biochemical markers within 
the control group pre- and postintervention. No side effect was reported with use of either intervention. 
DISCUSSION 
The main finding of this study was the ability of natural honey to modulate some of the cardiovascular 
risk factors. Although some results were statistically insignificant, they might be clinically important and 
they could be statistically significant when honey is used for a longer period. Present results are 
substantiated by previous work showing that honey could ameliorate cardiovascular risk factors after 2 
weeks of commencement of its ingestion[19]. This is extremely important, not only because 
cardiovascular diseases are a leading cause of death beside cancer, but using honey is a novel approach 
because honey is a natural nutritional material. Honey could provide the body with invaluable nutritional 
ingredients as well as antioxidant substances. Basically, the mechanism of action of honey is not clear; 
however, honey contains many trace elements, such as copper, zinc, antioxidants, and unidentified 
materials. Its content of fructose and glucose might have an important role in its effect. 
Natural honey decreased total cholesterol and LDL-C in overweight healthy and overweight 
hyperlipidemic subjects. Increasing dietary fructose from 3 to 20% of calories at the expense of starch 
increased total cholesterol by 9% and LDL-C by 11%[20]. Therefore, sucrose might increase lipids 
because of the presence of fructose. Honey contains fructose, but it decreased blood lipid levels. The 
difference between the effects of sucrose and natural honeys on cholesterol might be due to the presence 
of certain substances in natural honey[19]. 
Cardiac risk factors, such as obesity, smoking, hypertension, and chronic periodontal disease, are 
associated with elevated CRP levels. CRP may be involved in the pathogenesis of atherothrombosis[21]. 
CRP also decreased endothelial nitric oxide (NO) release and this effect remained unchanged by 
hyperglycemia. Through decreasing NO synthesis, CRP may facilitate the development of diverse 
cardiovascular diseases[22]. In the present study, honey reduced CRP, a marker of inflammation. Al-
Waili reported for the first time that oral honey could reduce plasma and urinary PGE2, PGF2-alpha, and 
thromboxane B2[23]. Therefore, it appears that honey has anti-inflammatory properties that make it a 
suitable nutrient to be used in acute or chronic inflammatory conditions[19]. Many reports have 
demonstrated lowering effects of antioxidants on CRP levels[24,25]. Honey contains many antioxidants; 
therefore, honey might reduce CRP by its antioxidant properties[19]. 
High-carbohydrate/low-fat, isocaloric diets have been shown to increase plasma triglyceride 
concentrations. Fructose feeding resulted in hyperinsulinemia and elevated blood pressure when 
compared with that in controls[26]. Both chronic and acute consumption of large amounts of fructose are 
reported to elevate triglyceride levels[27,28]. However, low doses of fructose added to glucose caused 
significant decline in triglyceride levels[28]. It was found that a fructose diet had no persistent effect on 
total cholesterol, HDL-C, or LDL-C[29]. In addition, a hypertriglyceridemic effect of fructose was not 
observed when fructose was provided by honey in rats[28]. Repeated intravenous infusion of honey 
reduced FBG, and intravenous administration of honey slowly or rapidly caused lower hyperglycemia 
than that obtained with use of dextrose[30]. This might be due to stimulation of insulin secretion, 
stimulation of glucose liver uptake by glucokinase, and presence of fructose with glucose that might 
reduce hyperglycemic response of the glucose content of honey. Significant reduction of triglyceride 
levels was observed after acute blood loss when rats were fed honey[31]. 
Honey increased the serum level of zinc and copper that is important for insulin and glucose 
metabolism[16]. Glucose tolerance testing demonstrated improved glucose tolerance in a high-fructose 
diet, which may be related to increased insulin receptor substrate-2 expression[32]. In normal adults and 
adults with type 2 diabetes, a small dose of fructose administered with glucose decreased the glycemic 
response to a glucose load[33,34]. Low-dose fructose improved the glycemic response to an oral glucose 
load in normal adults without significantly enhancing the insulin or triglyceride response[33]. It was Yaghoobi et al.: Honey and Cardiovascular Risk Factors  TheScientificWorldJOURNAL (2008) 8, 463–469 
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found that a small amount of fructose could increase hepatic glucose uptake and glycogen storage, and 
reduce glycemia and insulin level in dogs[35]. In addition, honey could reduce prostaglandin levels and 
elevate NO. It was demonstrated that PGE2 is one of the major physiological inhibitors of insulin, acting 
via specific receptors[36]. IL-1beta and PGE2 are two well-recognized inhibitors of glucose-induced 
insulin secretion and endogenous PGE2 mediates the inhibitory effects of IL-1beta on beta-cell 
function[37]. In addition, different NO donors stimulated a marked increase in insulin secretion[38]. 
Therefore, honey might partly affect glucose levels through its effects on prostaglandin and NO 
production.  
Honey may have a fantastic effect on modifying the traditional cardiovascular risk factors. 
Specifically, the role of honey in weight reduction, which can be confirmed with prospective huge sample 
studies, would be attractive. These present findings encourage the use of honey for a longer term to see its 
effect over time and pave the way for larger randomized controlled studies.  
CONCLUSION 
Consumption of natural honey in overweight and obese subjects reduced cardiovascular risk factors, 
particularly in subjects with elevated risk factors, and it did not increase body weight in overweight or 
obese subjects. The cardioprotective effects of honey may be partly explained by its anti-inflammatory 
effect.   
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